Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice

BACKGROUND: Vaccines that block human-to-mosquito Plasmodium transmission are needed for malaria eradication, and clinical trials have targeted zygote antigen Pfs25 for decades. We reported that a Pfs25 protein-protein conjugate vaccine formulated in alum adjuvant induced serum functional activity i...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Invest
Auteurs principaux: Healy, Sara A., Anderson, Charles, Swihart, Bruce J., Mwakingwe, Agnes, Gabriel, Erin E., Decederfelt, Hope, Hobbs, Charlotte V., Rausch, Kelly M., Zhu, Daming, Muratova, Olga, Herrera, Raul, Scaria, Puthupparampil V., MacDonald, Nicholas J., Lambert, Lynn E., Zaidi, Irfan, Coelho, Camila H., Renn, Jonathan P., Wu, Yimin, Narum, David L., Duffy, Patrick E.
Format: Artigo
Langue:Inglês
Publié: American Society for Clinical Investigation 2021
Sujets:
Clinical Medicine
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8011888/
https://ncbi.nlm.nih.gov/pubmed/33561016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI146221
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires